New agents that target senescent cells: The flavone, fisetin, and the BCL-XL inhibitors, A1331852 and A1155463

Yi Zhu, Ewald J. Doornebal, Tamar Pirtskhalava, Nino Giorgadze, Mark Wentworth, Heike Fuhrmann-Stroissnigg, Laura J. Niedernhofer, Paul D. Robbins, Tamara Tchkonia, James L. Kirkland

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

Senescent cells accumulate with aging and at sites of pathology in multiple chronic diseases. Senolytics are drugs that selectively promote apoptosis of senescent cells by temporarily disabling the pro-survival pathways that enable senescent cells to resist the pro-apoptotic, pro-inflammatory factors that they themselves secrete. Reducing senescent cell burden by genetic approaches or by administering senolytics delays or alleviates multiple age- and disease-related adverse phenotypes in preclinical models. Reported senolytics include dasatinib, quercetin, navitoclax (ABT263), and piperlongumine. Here we report that fisetin, a naturallyoccurring flavone with low toxicity, and A1331852 and A1155463, selective BCL-XL inhibitors that may have less hematological toxicity than the less specific BCL-2 family inhibitor navitoclax, are senolytic. Fisetin selectively induces apoptosis in senescent but not proliferating human umbilical vein endothelial cells (HUVECs). It is not senolytic in senescent IMR90 cells, a human lung fibroblast strain, or primary human preadipocytes. A1331852 and A1155463 are senolytic in HUVECs and IMR90 cells, but not preadipocytes. These agents may be better candidates for eventual translation into clinical interventions than some existing senolytics, such as navitoclax, which is associated with hematological toxicity.

Original languageEnglish (US)
Pages (from-to)1-9
Number of pages9
JournalAging
Volume9
Issue number3
DOIs
StatePublished - Jan 1 2017

Fingerprint

flavone
Human Umbilical Vein Endothelial Cells
Apoptosis
Quercetin
fisetin
Fibroblasts

Keywords

  • Adipose-derived stem cells
  • Aging
  • Apoptosis
  • BCL-X inhibitors
  • Flavonoids
  • Preadipocytes
  • Senolytics

Cite this

Zhu, Y., Doornebal, E. J., Pirtskhalava, T., Giorgadze, N., Wentworth, M., Fuhrmann-Stroissnigg, H., ... Kirkland, J. L. (2017). New agents that target senescent cells: The flavone, fisetin, and the BCL-XL inhibitors, A1331852 and A1155463. Aging, 9(3), 1-9. https://doi.org/10.18632/aging.101202

New agents that target senescent cells : The flavone, fisetin, and the BCL-XL inhibitors, A1331852 and A1155463. / Zhu, Yi; Doornebal, Ewald J.; Pirtskhalava, Tamar; Giorgadze, Nino; Wentworth, Mark; Fuhrmann-Stroissnigg, Heike; Niedernhofer, Laura J.; Robbins, Paul D.; Tchkonia, Tamara; Kirkland, James L.

In: Aging, Vol. 9, No. 3, 01.01.2017, p. 1-9.

Research output: Contribution to journalArticle

Zhu, Y, Doornebal, EJ, Pirtskhalava, T, Giorgadze, N, Wentworth, M, Fuhrmann-Stroissnigg, H, Niedernhofer, LJ, Robbins, PD, Tchkonia, T & Kirkland, JL 2017, 'New agents that target senescent cells: The flavone, fisetin, and the BCL-XL inhibitors, A1331852 and A1155463', Aging, vol. 9, no. 3, pp. 1-9. https://doi.org/10.18632/aging.101202
Zhu Y, Doornebal EJ, Pirtskhalava T, Giorgadze N, Wentworth M, Fuhrmann-Stroissnigg H et al. New agents that target senescent cells: The flavone, fisetin, and the BCL-XL inhibitors, A1331852 and A1155463. Aging. 2017 Jan 1;9(3):1-9. https://doi.org/10.18632/aging.101202
Zhu, Yi ; Doornebal, Ewald J. ; Pirtskhalava, Tamar ; Giorgadze, Nino ; Wentworth, Mark ; Fuhrmann-Stroissnigg, Heike ; Niedernhofer, Laura J. ; Robbins, Paul D. ; Tchkonia, Tamara ; Kirkland, James L. / New agents that target senescent cells : The flavone, fisetin, and the BCL-XL inhibitors, A1331852 and A1155463. In: Aging. 2017 ; Vol. 9, No. 3. pp. 1-9.
@article{0fd894279a694d31ba6eb5730496feb2,
title = "New agents that target senescent cells: The flavone, fisetin, and the BCL-XL inhibitors, A1331852 and A1155463",
abstract = "Senescent cells accumulate with aging and at sites of pathology in multiple chronic diseases. Senolytics are drugs that selectively promote apoptosis of senescent cells by temporarily disabling the pro-survival pathways that enable senescent cells to resist the pro-apoptotic, pro-inflammatory factors that they themselves secrete. Reducing senescent cell burden by genetic approaches or by administering senolytics delays or alleviates multiple age- and disease-related adverse phenotypes in preclinical models. Reported senolytics include dasatinib, quercetin, navitoclax (ABT263), and piperlongumine. Here we report that fisetin, a naturallyoccurring flavone with low toxicity, and A1331852 and A1155463, selective BCL-XL inhibitors that may have less hematological toxicity than the less specific BCL-2 family inhibitor navitoclax, are senolytic. Fisetin selectively induces apoptosis in senescent but not proliferating human umbilical vein endothelial cells (HUVECs). It is not senolytic in senescent IMR90 cells, a human lung fibroblast strain, or primary human preadipocytes. A1331852 and A1155463 are senolytic in HUVECs and IMR90 cells, but not preadipocytes. These agents may be better candidates for eventual translation into clinical interventions than some existing senolytics, such as navitoclax, which is associated with hematological toxicity.",
keywords = "Adipose-derived stem cells, Aging, Apoptosis, BCL-X inhibitors, Flavonoids, Preadipocytes, Senolytics",
author = "Yi Zhu and Doornebal, {Ewald J.} and Tamar Pirtskhalava and Nino Giorgadze and Mark Wentworth and Heike Fuhrmann-Stroissnigg and Niedernhofer, {Laura J.} and Robbins, {Paul D.} and Tamara Tchkonia and Kirkland, {James L.}",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/aging.101202",
language = "English (US)",
volume = "9",
pages = "1--9",
journal = "Aging",
issn = "0002-0966",
publisher = "US Administration on Aging",
number = "3",

}

TY - JOUR

T1 - New agents that target senescent cells

T2 - The flavone, fisetin, and the BCL-XL inhibitors, A1331852 and A1155463

AU - Zhu, Yi

AU - Doornebal, Ewald J.

AU - Pirtskhalava, Tamar

AU - Giorgadze, Nino

AU - Wentworth, Mark

AU - Fuhrmann-Stroissnigg, Heike

AU - Niedernhofer, Laura J.

AU - Robbins, Paul D.

AU - Tchkonia, Tamara

AU - Kirkland, James L.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Senescent cells accumulate with aging and at sites of pathology in multiple chronic diseases. Senolytics are drugs that selectively promote apoptosis of senescent cells by temporarily disabling the pro-survival pathways that enable senescent cells to resist the pro-apoptotic, pro-inflammatory factors that they themselves secrete. Reducing senescent cell burden by genetic approaches or by administering senolytics delays or alleviates multiple age- and disease-related adverse phenotypes in preclinical models. Reported senolytics include dasatinib, quercetin, navitoclax (ABT263), and piperlongumine. Here we report that fisetin, a naturallyoccurring flavone with low toxicity, and A1331852 and A1155463, selective BCL-XL inhibitors that may have less hematological toxicity than the less specific BCL-2 family inhibitor navitoclax, are senolytic. Fisetin selectively induces apoptosis in senescent but not proliferating human umbilical vein endothelial cells (HUVECs). It is not senolytic in senescent IMR90 cells, a human lung fibroblast strain, or primary human preadipocytes. A1331852 and A1155463 are senolytic in HUVECs and IMR90 cells, but not preadipocytes. These agents may be better candidates for eventual translation into clinical interventions than some existing senolytics, such as navitoclax, which is associated with hematological toxicity.

AB - Senescent cells accumulate with aging and at sites of pathology in multiple chronic diseases. Senolytics are drugs that selectively promote apoptosis of senescent cells by temporarily disabling the pro-survival pathways that enable senescent cells to resist the pro-apoptotic, pro-inflammatory factors that they themselves secrete. Reducing senescent cell burden by genetic approaches or by administering senolytics delays or alleviates multiple age- and disease-related adverse phenotypes in preclinical models. Reported senolytics include dasatinib, quercetin, navitoclax (ABT263), and piperlongumine. Here we report that fisetin, a naturallyoccurring flavone with low toxicity, and A1331852 and A1155463, selective BCL-XL inhibitors that may have less hematological toxicity than the less specific BCL-2 family inhibitor navitoclax, are senolytic. Fisetin selectively induces apoptosis in senescent but not proliferating human umbilical vein endothelial cells (HUVECs). It is not senolytic in senescent IMR90 cells, a human lung fibroblast strain, or primary human preadipocytes. A1331852 and A1155463 are senolytic in HUVECs and IMR90 cells, but not preadipocytes. These agents may be better candidates for eventual translation into clinical interventions than some existing senolytics, such as navitoclax, which is associated with hematological toxicity.

KW - Adipose-derived stem cells

KW - Aging

KW - Apoptosis

KW - BCL-X inhibitors

KW - Flavonoids

KW - Preadipocytes

KW - Senolytics

UR - http://www.scopus.com/inward/record.url?scp=85016619121&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016619121&partnerID=8YFLogxK

U2 - 10.18632/aging.101202

DO - 10.18632/aging.101202

M3 - Article

C2 - 28273655

AN - SCOPUS:85016619121

VL - 9

SP - 1

EP - 9

JO - Aging

JF - Aging

SN - 0002-0966

IS - 3

ER -